Adenylosuccinic acid

Cat. No.:	HY-127137	ŎН
CAS No.:	19046-78-7	0
Molecular Formula:	C ₁₄ H ₁₈ N ₅ O ₁₁ P	HO
Molecular Weight:	463.29	ÖN
Target:	Endogenous Metabolite	N N
Pathway:	Metabolic Enzyme/Protease	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	HO V O

DIOLOGICALACITY			
Description	Adenylosuccinic acid (Adenylosuccinate; Aspartyl adenylate) is a purine ribonucleoside monophosphate and plays a role in nucleotide cycle metabolite. Adenylosuccinic acid can be converted into fumaric acid through adenylosuccinate lyase. Adenylosuccinic acid has the potential for the study of duchenne muscular dystrophy(DMD) ^[1] .		
IC ₅₀ & Target	Human Endogenous Metabolite		
In Vivo	Adenylosuccinic acid (oral administration; 3-3000 μg/mL; 6 weeks) significantly improves the features of murine DMD, it decreases the number of centronucleated fibres, lipid accumulation, connective tissue infiltration and Ca ²⁺ content of mdx tibialis anterior ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	C57Bl/10ScSn (normal wild-type strain; Con) and C57Bl/10mdx (mdx) mice $^{[1]}$	
	Dosage:	3 μg/mL, 30 μg/mL, 300 μg/mL, 3000 μg/mL	
	Administration:	3 μg/mL for 3 days and 30 μg/mL for the next 4 days, and 300 μg/mL for one week, and then 3000 μg/mL for 6 weeks	
	Result:	Ameliorated the symptoms of murine duchenne muscular dystrophy.	

REFERENCES

[1]. Timpani CA, et al. Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy. Sci Rep. 2020 Jan 24;10(1):1125.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fa

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Product Data Sheet



Page 1 of 1

Addroses 1 Deer Derle Dr. C. '